{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:51:38Z","timestamp":1760143898585,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.lpm.2020.104038","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T11:08:10Z","timestamp":1593860890000},"page":"104038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Updates in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis: At a crossroad"],"prefix":"10.1016","volume":"49","author":[{"given":"Stephanie","family":"Garner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader","family":"Khalidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lpm.2020.104038_bib0320","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0002-9343(67)90144-1","article-title":"Long-term follow-up study of periarteritis nodosa","volume":"43","author":"Frohnert","year":"1967","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.lpm.2020.104038_bib0325","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.lpm.2020.104038_bib0330","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener's granulomatosis: studies in eighteen patients and a review of the literature","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.lpm.2020.104038_bib0335","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.lpm.2020.104038_bib0340","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.lpm.2020.104038_bib0345","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","article-title":"BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis","volume":"53","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.lpm.2020.104038_bib0350","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.25061","article-title":"Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review","volume":"62","author":"Monach","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.lpm.2020.104038_bib0355","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.lpm.2020.104038_bib0360","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.lpm.2020.104038_bib0365","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/art.21117","article-title":"Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)","volume":"52","author":"Seo","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.lpm.2020.104038_bib0370","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1191\/0961203304lu1063oa","article-title":"Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy","volume":"13","author":"Park","year":"2004","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.lpm.2020.104038_bib0375","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/art.20240","article-title":"Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis","volume":"51","author":"Langford","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3\u20134","key":"10.1016\/j.lpm.2020.104038_bib0380","first-page":"c100","article-title":"Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis","volume":"102","author":"Koukoulaki","year":"2006","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"10.1016\/j.lpm.2020.104038_bib0385","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ndt\/gfm780","article-title":"Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement","volume":"23","author":"Hu","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.lpm.2020.104038_bib0390","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2006.060301","article-title":"Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide","volume":"66","author":"Stassen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2020.104038_bib0395","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"5 Pt 1","key":"10.1016\/j.lpm.2020.104038_bib0400","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0091-6749(99)70434-3","article-title":"Differential B- and T-cell activation in Wegener's granulomatosis","volume":"103","author":"Popa","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.lpm.2020.104038_bib0405","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1074-7613(04)00112-8","article-title":"Pathogenic roles of B cells in human autoimmunity; insights from the clinic","volume":"20","author":"Martin","year":"2004","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.lpm.2020.104038_bib0410","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.lpm.2020.104038_bib0415","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.lpm.2020.104038_bib0420","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial","volume":"173","author":"Keogh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.lpm.2020.104038_bib0425","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2020.104038_bib0430","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lpm.2020.104038_bib0435","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.lpm.2020.104038_bib0440","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.lpm.2020.104038_bib0445","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/art.34547","article-title":"Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Faurschou","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.lpm.2020.104038_bib0450","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.lpm.2020.104038_bib0455","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.lpm.2020.104038_bib0460","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lpm.2020.104038_bib0465","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.lpm.2020.104038_bib0470","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13063-017-1857-z","article-title":"Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial","volume":"18","author":"Gopaluni","year":"2017","journal-title":"Trials"},{"issue":"8","key":"10.1016\/j.lpm.2020.104038_bib0475","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"10.1016\/j.lpm.2020.104038_bib0480","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.lpm.2020.104038_bib0485","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","article-title":"Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis","volume":"46","author":"Metzler","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.lpm.2020.104038_bib0490","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1001\/archinte.1991.00400080133026","article-title":"Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim","volume":"151","author":"Valeriano-Marcet","year":"1991","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.lpm.2020.104038_bib0495","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1001\/archinte.1988.00380100131030","article-title":"Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis","volume":"148","author":"Israel","year":"1988","journal-title":"Arch Intern Med"},{"issue":"Suppl.\u00a06","key":"10.1016\/j.lpm.2020.104038_bib0500","first-page":"825","article-title":"Chronic crusting, nasal carriage of Staphylococcus aureus and relapse rate in pulmonary Wegener's granulomatosis","volume":"59","author":"Zycinska","year":"2008","journal-title":"J Physiol Pharmacol"},{"issue":"4","key":"10.1016\/j.lpm.2020.104038_bib0505","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/archotol.1989.01860280113028","article-title":"Three cases of Wegener's granulomatosis treated with an antimicrobial agent","volume":"115","author":"Fukuda","year":"1989","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"1","key":"10.1016\/j.lpm.2020.104038_bib0510","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis","volume":"335","author":"Stegeman","year":"1996","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lpm.2020.104038_bib0515","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/art.20234","article-title":"Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis","volume":"51","author":"Slot","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.lpm.2020.104038_bib0520","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.lpm.2020.104038_bib0525","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","article-title":"Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse","volume":"19","author":"Morgan","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.lpm.2020.104038_bib0530","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.lpm.2020.104038_bib0535","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/rheumatology\/keq244","article-title":"Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission","volume":"49","author":"Pierrot-Deseilligny Despujol","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.lpm.2020.104038_bib0540","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2215\/CJN.00100114","article-title":"Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis","volume":"9","author":"Walsh","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.lpm.2020.104038_bib0545","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MD.0000000000000020","article-title":"Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration","volume":"93","author":"Springer","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.lpm.2020.104038_bib0550","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ndt\/gfw211","volume":"31","author":"Sanders","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.lpm.2020.104038_bib0555","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.lpm.2020.104038_bib0560","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.lpm.2020.104038_bib0565","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.lpm.2020.104038_bib0570","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/keq351","article-title":"Mortality in Wegener's granulomatosis: a bimodal pattern","volume":"50","author":"Luqmani","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.lpm.2020.104038_bib0575","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the anca-associated vasculitides: long-term data from the European vasculitis study grup (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.lpm.2020.104038_bib0580","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann Rheum Dis"},{"year":"2017","key":"10.1016\/j.lpm.2020.104038_bib0585"},{"key":"10.1016\/j.lpm.2020.104038_bib0590","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1745-6215-14-73","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial","volume":"14","author":"Walsh","year":"2013","journal-title":"Trials"},{"year":"2018","series-title":"The effects of plasma exchange and reduced-dose glucocorticoids during remission-induction for treatment of severe ANCA-associated vasculitis. American College of Rheumatology Scientific Meeting","key":"10.1016\/j.lpm.2020.104038_bib0595"},{"issue":"2","key":"10.1016\/j.lpm.2020.104038_bib0600","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semarthrit.2018.01.013","article-title":"Reducing glucocorticoid duration in ANCA-associated vasculitis: a pilot trial","volume":"48","author":"Miloslavsky","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.lpm.2020.104038_bib0605","doi-asserted-by":"crossref","first-page":"e018748","DOI":"10.1136\/bmjopen-2017-018748","article-title":"Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial","volume":"7","author":"Furuta","year":"2017","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.lpm.2020.104038_bib0610","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.lpm.2020.104038_bib0615","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/13543784.2018.1472234","article-title":"Avacopan in the treatment of ANCA-associated vasculitis","volume":"27","author":"Tesar","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"10.1016\/j.lpm.2020.104038_bib0620","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s10067-017-3752-0","article-title":"Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review","volume":"36","author":"Sakai","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.lpm.2020.104038_bib0625","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/ndt\/gfp783","article-title":"Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis","volume":"25","author":"Nogueira","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.lpm.2020.104038_bib0630","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3109\/14397595.2016.1160968","article-title":"Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial","volume":"26","author":"Sakai","year":"2016","journal-title":"Mod Rheumatol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498220300269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498220300269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:07:43Z","timestamp":1760105263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498220300269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0755498220300269"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2020.104038","relation":{},"ISSN":["0755-4982"],"issn-type":[{"type":"print","value":"0755-4982"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis: At a crossroad","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2020.104038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104038"}}